The review was conducted according to PRISMA 2020 reporting standards and prospectively registered in PROSPERO under registration number CRD420261400459, with the registration dated 20 May 2026. The research team searched six bibliographic databases along with the ClinicalTrials.gov registry through 20 August 2026, applying no language restriction, and supplemented the electronic searches with backward citation searching of the included studies. Two reviewers independently screened records and full texts, extracted data, assessed risk of bias at the result level, and rated the certainty of the evidence, with disagreements resolved through discussion and, where necessary, adjudication by a third reviewer. This dual-reviewer architecture matters because systematic reviews live or die by the reproducibility of their selection and appraisal decisions; single-reviewer pipelines are a well-recognised source of error in the evidence-synthesis literature.

The scale of the underlying evidence base is the first striking finding. The searches identified 3,197 database records and 68 ClinicalTrials.gov entries, yet only eight reports describing six independent randomised trials met the inclusion criteria, and just five of those trials contributed quantitative data to the syntheses. For a condition as prevalent and disabling as endometriosis, that attrition rate from thousands of records to a handful of usable trials is itself a message about how little high-quality experimental work has been done. The trials that did qualify were small and heterogeneous, which constrained every downstream analysis the team attempted.

The statistical machinery the authors deployed deserves attention because it was chosen specifically to guard against the overconfidence that small samples can breed. Rather than relying on a single pooling approach, the team ran random-effects meta-analyses using restricted maximum likelihood estimation with Hartung-Knapp inference, a method that widens confidence intervals when the number of studies is small and between-study variance is uncertain. They also ran alternative small-k models as sensitivity analyses and computed prediction intervals, which estimate the range of effects a new trial in a comparable setting might plausibly show. The GRADE framework was applied using review-stage clinical decision thresholds to grade certainty for each outcome, and the result was unambiguous: certainty was rated as very low for all key outcomes.

The headline quantitative result concerns overall endometriosis-related pain, pooled across four trials with a combined 271 participants. The standardised mean difference was -0.36, with a 95 percent confidence interval spanning -0.95 to 0.24, meaning the interval crosses the null and cannot exclude either a substantial benefit or a modest harm. Heterogeneity was moderate, with an I-squared of 57.2 percent, and the prediction interval stretched from -1.74 to 1.03, an extraordinarily wide band that captures effects ranging from large improvement to no benefit at all. In plain terms, even the point estimate, which modestly favoured exercise, is compatible with almost any clinical reality a future trial might reveal.

The multidimensional symptom picture fared no better. Psychological distress, synthesised from three trials with 243 participants, yielded a standardised mean difference of -0.29 with a confidence interval of -1.43 to 0.85, a range so wide it is essentially uninformative. Sexual function, pooled from three trials totalling 144 participants, produced a mean difference of -2.23 with a confidence interval of -5.96 to 1.51 on the relevant instrument scale. Perhaps most tellingly, the authors report that statistical significance differed across random-effects specifications for five of their syntheses, meaning the conclusions were method-dependent: whether exercise appeared statistically significant depended on which defensible statistical model the analysts chose. Findings that flip with the choice of estimator are, by convention, treated as unstable rather than as evidence of a real effect.

Safety data added another layer of concern. Harms reporting across the included trials was inconsistent, making it impossible to characterise the adverse-effect profile of structured exercise in this population with any confidence. This is a recurring blind spot in exercise-intervention research generally, where physical activity is assumed to be benign and trialists often neglect systematic adverse-event collection. For women with endometriosis, whose symptoms can include deep dyspareunia and activity-provoked pelvic pain, the assumption that exercise is universally tolerable is not self-evident, and the absence of standardised harms data leaves clinicians without the information needed to counsel patients responsibly.

What does this mean for practice? The authors are careful to distinguish between the absence of evidence and evidence of absence. The point estimates across outcomes generally favoured exercise, and nothing in the analysis suggests structured training is harmful. Their conclusion is deliberately nuanced: decisions to use structured exercise should be individualised according to patient preference, general physical-activity guidance, comorbidity, and tolerance, rather than justified by an assumed endometriosis-specific benefit. In other words, a woman with endometriosis who enjoys swimming or yoga has every reason to continue for the same reasons exercise benefits anyone else, including cardiovascular and mental health, but she should not be told that the published trial evidence proves it will shrink her pain scores or her symptom burden.

The path forward, the review makes clear, runs through better trials. The evidence base needs larger, adequately powered randomised studies with standardised exercise protocols, validated multidimensional outcome measures such as the Endometriosis Health Profile-30 and the Female Sexual Function Index, pre-registered primary outcomes, and systematic harms reporting. Until such trials exist, the review stands as a corrective to the enthusiasm that has outpaced the data, a reminder that in evidence-based medicine, plausibility is not proof, and that even the most intuitively sensible interventions must earn their clinical recommendations the hard way, one well-designed trial at a time.

Subject of Research: Effects of structured exercise training on pain and symptom burden in women with endometriosis

Article Title: Effects of structured exercise training on pain and multidimensional symptom burden in women with endometriosis: an updated systematic review and meta-analysis

Article References: Sun, M., Zhu, Y., Wang, L., & Liang, W. (2026). Effects of structured exercise training on pain and multidimensional symptom burden in women with endometriosis: an updated systematic review and meta-analysis. BMC Psychology. https://doi.org/10.1186/s40359-026-05724-7

Image Credits: AI Generated

DOI: 10.1186/s40359-026-05724-7

Keywords: endometriosis, structured exercise, systematic review, meta-analysis, chronic pelvic pain, psychological distress, sexual function, quality of life, GRADE, randomised controlled trials, PROSPERO, BMC Psychology

Early onset type 2 diabetes, abbreviated EOT2D, is increasingly recognised by clinicians as a distinct and particularly aggressive clinical phenotype. Because it strikes in the third and fourth decades of life, the disease has decades longer to inflict damage on blood vessels, nerves, kidneys and the heart. People diagnosed young experience more rapid deterioration in blood sugar control, develop complications earlier, and face a lower life expectancy than those whose type 2 diabetes appears later in life. As rates of obesity rise across the globe, the number of young adults affected is climbing steeply, making the search for potent, disease-modifying interventions an urgent priority for health systems worldwide.

The biological rationale behind the trial, known as RESET for Remission, rests on the complementary effects of dietary energy restriction and exercise. Low energy diets have previously been shown to drive glucose levels below the diagnostic threshold for type 2 diabetes without the need for medication, a state defined as remission. Adding structured exercise may deliver synergistic advantages: greater cardiorespiratory fitness, preservation of muscle mass during rapid weight loss, enhanced cardiac function, and reduced insulin resistance. The researchers reasoned that a condition as aggressive as early onset type 2 diabetes merits an intervention powerful enough to arrest its swift evolution, and they designed the study to test whether combining the two approaches would outperform usual care.

The trial was a randomised, open-label, blinded endpoint efficacy study conducted across three centres in England and Canada, affiliated with the University of Leicester, McGill University in Montreal, and the University of Alberta in Edmonton. It enrolled adults aged 18 to 45 with early onset type 2 diabetes and obesity who were not taking insulin therapy. Between September 24, 2021 and June 6, 2025, a total of 96 participants were randomised, 40 in the United Kingdom and 56 in Canada. The intervention group comprised 24 women and 26 men, while the control group had 21 women and 25 men. The mean age of participants was 38 years and the mean body mass index was 35.2 kilograms per square metre. Notably, 86 participants, or 90 percent, attended final assessments, a retention rate that strengthens confidence in the findings.

The intervention itself was demanding but carefully structured. Participants stopped all glucose-lowering and blood pressure-lowering medication, in the absence of albuminuria, as they began an 800 to 900 kilocalorie per day diet providing 30 percent of energy from protein, 50 percent from carbohydrate and 20 percent from fat. They were encouraged to drink at least two litres of calorie-free fluid daily and were given a fibre-based laxative to use as required. The first two weeks consisted of total meal replacement using Optifast. From weeks 3 to 12, the same caloric intake continued with more variety, using Optifast in the United Kingdom and ProtiDiet in Canada, alongside one food-based meal per day supplying 60 to 90 grams of protein from all sources combined, one portion of fruit and two portions of non-starchy vegetables.

Exercise ran in parallel with the dietary phase. During weeks 1 to 12, participants completed twice-weekly supervised sessions covering both aerobic and resistance training, plus one weekly independent exercise session. From weeks 13 to 24, they transitioned to a weight-maintenance diet while continuing independent exercise. The primary outcome was remission at 24 weeks, defined as a glycated haemoglobin level below 6.5 percent, or 48 millimoles per mole, together with the absence of glucose-lowering medication for at least 12 weeks. The primary efficacy and harms analysis included all randomised individuals, with a conservative assumption that missing data meant no remission. Secondary endpoints captured cardiorespiratory fitness, body composition and cardiac structure.

The results were striking across multiple dimensions. Intervention participants, who averaged 100.7 kilograms at baseline, lost a mean of 8.4 kilograms by week 24, reaching an average weight of 92.3 kilograms. Control participants, who averaged 103.2 kilograms at the start, lost only 1.2 kilograms, ending at a mean of 102.0 kilograms. After statistical adjustment, the analysis showed that intervention participants lost 7.5 kilograms more than controls, including 6.6 additional kilograms of fat mass. Critically, the trial demonstrated that fat-free mass and muscle preservation are achievable even during rapid weight loss, a finding the authors attribute to the resistance training component that deliberately targeted muscle during the intensive dietary phase.

Safety data were reassuring. Remission was achieved without any severe adverse events. Most participants in the intervention group, 43 of 50, experienced at least one adverse event, compared with 6 of 46 in the control group, but these were mainly the familiar early effects of very low energy diets, such as constipation, headache, dizziness and fatigue, all of which resolved. This profile mirrors what has been reported in previous meal replacement trials and suggests that, under appropriate supervision, the intervention is tolerable for the majority of young adults willing to undertake it.

The authors emphasised the breadth of the benefits beyond blood sugar control. In their summary of the RESET for Remission findings, they report that combining structured aerobic and resistance exercise with a low-calorie diet produced high remission rates, induced fat loss while preserving muscle mass, improved muscle quality and function, enhanced cardiovascular health, and led to meaningful improvements in patient-reported outcomes. They noted that their remission rates sit at the upper end of those previously reported in the literature for trials of similar duration, and that this is the first time such effects have been demonstrated in a multi-ethnic population with early onset type 2 diabetes through a combined low energy diet and structured exercise intervention.

The researchers are candid about the challenges that remain. All weight loss programmes, including low energy diets used for type 2 diabetes remission, are typically followed by a period of partial or full weight regain for most people. Because weight loss driven by lower energy intake alone reduces both fat and fat-free mass, and there is some evidence that weight regain may preferentially restore fat over fat-free mass, there is a long-term risk of net muscle loss and increased sarcopenia. Preserving muscle during remission-oriented weight loss, they argue, may have important implications for long-term metabolic health, physical function and disease trajectory, though this requires confirmation in longer-term studies. They also highlight that their approach may be particularly valuable for those seeking or with potential for pregnancy, a group in which medication options are limited. As the global prevalence of early onset type 2 diabetes continues to rise, the team concludes that the findings present an opportunity to re-evaluate treatment paradigms and support scalable implementation of integrated dietary and exercise interventions, pending further evaluation in real-world settings.

Subject of Research: Remission of early onset type 2 diabetes through a combined low energy diet and structured exercise intervention

Article Title: Study shows low energy diet combined with structured exercise reverses early onset type 2 diabetes in half of participants

Article References: Study shows low energy diet combined with structured exercise reverses early onset type 2 diabetes in half of participants. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: type 2 diabetes, diabetes remission, low energy diet, structured exercise, early onset diabetes, randomised controlled trial, weight loss, resistance training, McGill University, University of Leicester, EASD, The Lancet Regional Health Americas